Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Extracellular vesicles as precision therapeutics for psychiatric conditions: targeting interactions among neuronal, glial, and immune networks

I. Kawiková, V. Špička, JCK. Lai, PW. Askenase, L. Wen, Z. Kejík, M. Jakubek, K. Valeš, F. Španiel

. 2025 ; 16 (-) : 1454306. [pub] 20250408

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016145

The critical role of the immune system in brain function and dysfunction is well recognized, yet development of immune therapies for psychiatric diseases has been slow due to concerns about iatrogenic immune deficiencies. These concerns are emphasized by the lack of objective diagnostic tools in psychiatry. A promise to resolve this conundrum lies in the exploitation of extracellular vesicles (EVs) that are physiologically produced or can be synthetized. EVs regulate recipient cell functions and offer potential for EVs-based therapies. Intranasal EVs administration enables the targeting of specific brain regions and functions, thereby facilitating the design of precise treatments for psychiatric diseases. The development of such therapies requires navigating four dynamically interacting networks: neuronal, glial, immune, and EVs. These networks are profoundly influenced by brain fluid distribution. They are crucial for homeostasis, cellular functions, and intercellular communication. Fluid abnormalities, like edema or altered cerebrospinal fluid (CSF) dynamics, disrupt these networks, thereby negatively impacting brain health. A deeper understanding of the above-mentioned four dynamically interacting networks is vital for creating diagnostic biomarker panels to identify distinct patient subsets with similar neuro-behavioral symptoms. Testing the functional pathways of these biomarkers could lead to new therapeutic tools. Regulatory approval will depend on robust preclinical data reflecting progress in these interdisciplinary areas, which could pave the way for the design of innovative and precise treatments. Highly collaborative interdisciplinary teams will be needed to achieve these ambitious goals.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016145
003      
CZ-PrNML
005      
20250731091541.0
007      
ta
008      
250708e20250408sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2025.1454306 $2 doi
035    __
$a (PubMed)40264776
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kawiková, Ivana $u National Institute of Mental Health, Klecany, Czechia $u Department of Medicine, Yale School of Medicine, New Haven, CT, United States $u Department of Biology, Hartford University, West Hartford, CT, United States
245    10
$a Extracellular vesicles as precision therapeutics for psychiatric conditions: targeting interactions among neuronal, glial, and immune networks / $c I. Kawiková, V. Špička, JCK. Lai, PW. Askenase, L. Wen, Z. Kejík, M. Jakubek, K. Valeš, F. Španiel
520    9_
$a The critical role of the immune system in brain function and dysfunction is well recognized, yet development of immune therapies for psychiatric diseases has been slow due to concerns about iatrogenic immune deficiencies. These concerns are emphasized by the lack of objective diagnostic tools in psychiatry. A promise to resolve this conundrum lies in the exploitation of extracellular vesicles (EVs) that are physiologically produced or can be synthetized. EVs regulate recipient cell functions and offer potential for EVs-based therapies. Intranasal EVs administration enables the targeting of specific brain regions and functions, thereby facilitating the design of precise treatments for psychiatric diseases. The development of such therapies requires navigating four dynamically interacting networks: neuronal, glial, immune, and EVs. These networks are profoundly influenced by brain fluid distribution. They are crucial for homeostasis, cellular functions, and intercellular communication. Fluid abnormalities, like edema or altered cerebrospinal fluid (CSF) dynamics, disrupt these networks, thereby negatively impacting brain health. A deeper understanding of the above-mentioned four dynamically interacting networks is vital for creating diagnostic biomarker panels to identify distinct patient subsets with similar neuro-behavioral symptoms. Testing the functional pathways of these biomarkers could lead to new therapeutic tools. Regulatory approval will depend on robust preclinical data reflecting progress in these interdisciplinary areas, which could pave the way for the design of innovative and precise treatments. Highly collaborative interdisciplinary teams will be needed to achieve these ambitious goals.
650    12
$a extracelulární vezikuly $x imunologie $x metabolismus $x transplantace $7 D000067128
650    _2
$a lidé $7 D006801
650    12
$a duševní poruchy $x terapie $x imunologie $x metabolismus $7 D001523
650    12
$a neurony $x metabolismus $x imunologie $7 D009474
650    _2
$a zvířata $7 D000818
650    12
$a neuroglie $x metabolismus $x imunologie $7 D009457
650    _2
$a mezibuněčná komunikace $7 D002450
650    12
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a biologické markery $7 D015415
650    _2
$a mozek $x imunologie $x metabolismus $7 D001921
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Špička, Václav $u Institute of Physics of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Lai, James C K $u Department of Biomedical and Pharmaceutical Sciences, Idaho State University College of Pharmacy, Pocatello, ID, United States $u Department of Diagnostic Radiology and Biomedical Imaging, Magnetic Resonance Research Center, Yale School of Medicine, New Haven, CT, United States
700    1_
$a Askenase, Philip W $u Department of Medicine, Yale School of Medicine, New Haven, CT, United States
700    1_
$a Wen, Li $u Department of Medicine, Yale School of Medicine, New Haven, CT, United States
700    1_
$a Kejík, Zdeněk $u Biotechnology and Biomedical Center in Vestec (BIOCEV) , First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia
700    1_
$a Jakubek, Milan $u Biotechnology and Biomedical Center in Vestec (BIOCEV) , First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia
700    1_
$a Valeš, Karel $u National Institute of Mental Health, Klecany, Czechia $u 3rd Medical Faculty, Charles University, Prague, Czechia
700    1_
$a Španiel, Filip $u National Institute of Mental Health, Klecany, Czechia $u 3rd Medical Faculty, Charles University, Prague, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 16 (20250408), s. 1454306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40264776 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091536 $b ABA008
999    __
$a ok $b bmc $g 2366763 $s 1253270
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 16 $c - $d 1454306 $e 20250408 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace